


Supplementary Material:

Analysis of the Tyrosine Kinome in Melanoma Reveals Recurrent Mutations in *ERBB4*


Todd D. Prickett, Neena S. Agrawal, Xiaomu Wei, Kristin E. Yates, Jimmy C. Lin, John Wunderlich, Julia C. Cronin, Pedro Cruz, NISC Comparative Sequencing Program, Steven A. Rosenberg, Yardena Samuels*

* Corresponding author: Yardena Samuels, National Human Genome Research Institute, NIH, 50 South Drive, MSC 8000, Building 50, Room 5140, Bethesda MD 20892-8000, Phone: 301-451-2628, Fax: 301-480-9864, Email: samuelsy@mail.nih.gov

Supplementary Figures




Supplementary Figure 1. Detection of mutations in ERBB4. Representative examples of mutations in ERBB4. In each case, the top sequence chromatogram was obtained from normal tissue and the lower sequence chromatogram from the indicated tumors. Arrows indicate the location of missense mutations. The nucleotide and amino acid alterations are indicated below the chromatograms.




Supplementary Figure 2. Mutation spectra of single base pair substitutions.

A. Kinome mutation spectrum. The number of each of the six classes of base substitutions resulting in nonsynonymous changes in the kinome screen is shown. B. Mutation spectra of single base pair substitutions in ERBB4. The number of each of the six classes of base substitutions resulting in nonsynonymous changes in ERBB4 is shown.




Supplementary Figure 3. Distribution of mutations in ERBB4, FLT1, EphB2, EphB6, PTK2B, and TIE1. Black arrows indicate positions of nonsynonymous mutations and boxes represent functional domains (Rcpt L, Receptor L; GFR, Growth Factor Receptor; PTK, Protein Tyrosine Kinase; IG, Immunoglobulin; IGc2, Immunoglobulin C-2 Type; Eph Rcpt, Ephrin Receptor; FNIII, Fibronectin Type III; SAM, Sterile Alpha Motif; FERM, Protein 4.1, Ezrin, Radixin, Moesin (FERM) Domain; Focal AT, Focal Adhesion Targeting Region)


A






B




Supplementary Figure 4. Ribbon diagrams of ERBB4. A. Distribution of ERBB4 mutations in a ribbon diagram of its extracellular domain (PDB ID 2ahx). The two views are related to one another by a 180° rotation about a vertical axis. α -helices are shown in red, β -sheets are shown in blue, and loops are shown in black. All mutations are represented as space-filling molecules. ERBB4 mutations are shown in yellow, and the equivalent positions of known activating EGFR mutations are shown in green. The receptor L domain is denoted by black circles, the growth factor receptor domain is denoted by purple circles and cloned ERBB4 mutants are highlighted in red. B. Distribution of ERBB4 mutations in a ribbon of its kinase domain (PDB ID 2r4b). The two views are related to one another by a 180° rotation about a vertical axis. α -helices are shown in red, β -sheets are shown in blue, and loops are shown in black. All mutations are represented as space-filling molecules. ERBB4 mutations are shown in yellow, equivalent positions of known ERBB2 mutations are shown in cyan, and the equivalent positions of known activating EGFR mutations are shown in green. The activation loop is denoted by black circles. In A and B, Images were created by SWISS-MODEL. Determination of the location of previously reported EGFR and ERBB2 mutations is described in the experimental procedures and cloned ERBB4 mutants are highlighted in red.





Supplementary Figure 5. Effects of ERBB4 mutation on AKT and ERK phosphorylation. Melanoma cell lines, containing either WT or mutant ERBB4, were harvested and analyzed by immunoblot. Shown are immunoblots of lysates probed with the indicated antibodies (α -P-ERK1/2 (recognizes phosphorylation of T202 and Y204 on ERK1 and T185 and Y187 on ERK2).

A**B****C**



Supplementary Figure 6. Effect of ERBB4 mutations on cell growth in NIH 3T3 and SK-Mel-2 cells. A. Growth of NIH 3T3 cells expressing vector, WT ERBB4 or various ERBB4 missense mutants in soft agar. The graph indicates the number of colonies after 14 days. B. Detection of ERBB4 protein expression in stable transfectants of SK-Mel-2 melanoma cells by immunoblot analysis, lysates from the different clones stably transfected with an empty vector, human WT ERBB4 or the indicated ERBB4 mutants were immunoprecipitated and immunoblotted with ERBB4 antibody. C. Anchorage-independent proliferation of SK-Mel-2 cell clones expressing the indicated constructs was assessed by measuring colony formation in soft agar. Graph indicates number of colonies observed after 14 days of growth.



Supplementary Figure 7. Knockdown of ERBB4 protein causes reduced activation of the AKT pathway but not of the ERK pathway. Melanoma cell lines, containing either WT or mutant ERBB4, were harvested and analyzed by western blot. Shown are immunoblots of lysates probed with the indicated antibodies (α -P-ERK1/2 (recognizes phosphorylation of T202 and Y204 on ERK1 and T185 and Y187 on ERK2)).

A**B**

Supplementary Figure 8. Rescue of oncogene dependence by exogenous non-targetable ERBB4. A. Melanoma cells harboring mutant ERBB4 and stably expressing control or ERBB4 shRNA #6 transduced with either vector or non targetable (NT) ERBB4 were analyzed by immunoprecipitation of lysates with α -ERBB4. Samples were analyzed by immunoblotting with the indicated antibodies. As a loading control lysates were immunoblotted with α -Tubulin. B. Melanoma cells expressing vector or the ERBB4 shRNA #6 transduced with a vector or NT ERBB4 were evaluated for cell proliferation by measuring the average cell number at each time point by determining DNA content using SYBR Green I.

A**B**

Supplementary Figure 9. Effect of lapatinib on ERK1/2 signaling pathways.

A. Melanoma lines expressing mutant ERBB4 exhibit increased lapatinib sensitivity with respect to ERK1 and ERK2 phosphorylation. Cells were treated for 72 hrs with 5 μ M lapatinib or vehicle as control. The activity of ERK1 and ERK2 was determined by immunoblotting with phospho-specific antibodies (α -P-ERK1/2 - recognizes phosphorylation of T202 and Y204 on ERK1 and T185 and Y187 on ERK2). Total ERK protein was also determined by immunoblotting. Shown are representative blots. B. Quantitative assessment of data from one melanoma cell line harboring WT ERBB4 and three melanoma cell lines harboring mutant ERBB4. The ratio of band intensities of P-ERK1/ERK1 or P-ERK2/ERK2 was analyzed for each melanoma cell line.

Table S1. Tyrosine Kinase genes analyzed

CCDS accession and amplimer number	Ref Seq accession and amplimer number	Gene Name	Gene Description
CCDS35165.1	NM_007313.2	ABL1/ABL	v-abl Abelson murine leukemia viral oncogene homolog 1
CCDS30947.1	NM_007314.2	ABL2/ARG	v-abl Abelson murine leukemia viral oncogene homolog 2 (arg, Abelson-related gene)
CCDS33928.1	NM_005781.4	ACK1/TNK2	tyrosine kinase, non-receptor, 2
CCDS33172.1	NM_004304.3	ALK	anaplastic lymphoma kinase (Ki-1)
CCDS12575.1	NM_021913.3	AXL	AXL receptor tyrosine kinase
CCDS5982.1	NM_001715.2	BLK	B lymphoid tyrosine kinase
CCDS14168.1	NM_203281.2	BMX	BMX non-receptor tyrosine kinase
CCDS13524.1	NM_005975.2	BRK/PTK6	PTK6 protein tyrosine kinase 6
CCDS14482.1	NM_000061.1	BTK	Bruton agammaglobulinemia tyrosine kinase
CCDS4302.1	NM_005211.2	CSF1R	colony stimulating factor 1 receptor, formerly McDonough feline sarcoma viral (v-fms) oncogene homolog
CCDS10269.1	NM_004383.1	CSK	c-src tyrosine kinase
CCDS4690.1	NM_001954.4	DDR1	discoidin domain receptor family, member 1
CCDS1241.1	NM_006182.2	DDR2	discoidin domain receptor family, member 2
CCDS5514.1	NM_005228.3	EGFR	epidermal growth factor receptor (erythroblastic leukemia viral (v-erb-b) oncogene homolog, avian)
CCDS5984.1	NM_005232.3	EPHA1	ephrin receptor EphA1
CCDS169.1	NM_004431.2	EPHA2	ephrin receptor EphA2
CCDS2922.1	NM_005233.5	EPHA3	ephrin receptor EphA3 isoform a precursor
CCDS2447.1	NM_004438.3	EPHA4	ephrin receptor EphA4
CCDS3514.1	NM_182472.1	EPHA5	ephrin receptor EphA5 isoform b
N/A	NM_001080448.2	EPHA6	EPH receptor A6 isoform a
CCDS5031.1	NM_004440.2	EPHA7	ephrin receptor EphA7
CCDS30626.1	NM_001006943.1	EPHA8	EPH receptor A8 isoform 2 precursor
CCDS425.1	NM_173641.2	EPHA10	EPH receptor A10 isoform 2
N/A	NM_004441.3	EPHB1	ephrin receptor EphB1 precursor
CCDS230.1	NM_004442.6	EPHB2	ephrin receptor EphB2 isoform 2 precursor
CCDS3268.1	NM_004443.3	EPHB3	ephrin receptor EphB3 precursor
CCDS5706.1	NM_004444.4	EPHB4	ephrin receptor EphB4 precursor
CCDS5873.1	NM_004445.2	EPHB6	ephrin receptor EphB6 precursor
CCDS32642.1	NM_004448.2	ERBB2	v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian)
CCDS31833.1	NM_001982.2	ERBB3	v-erb-b2 erythroblastic leukemia viral oncogene homolog 3 (avian)
CCDS2394.1	NM_005235.2	ERBB4	v-erb-a erythroblastic leukemia viral oncogene homolog 4 (avian)
CCDS6381.1	NM_153831.2	FAK/PTK2	PTK2 protein tyrosine kinase 2
CCDS4098.1	NM_005246.2	FER	fer (fps/fes related) tyrosine kinase (phosphoprotein NCP94)
CCDS10365.1	NM_002005.2	FES	V-FES feline sarcoma viral/V-FPS fujinami avian
CCDS6107.1	NM_023110.2	FGFR1	fibroblast growth factor receptor 1 (fms-related tyrosine kinase 2, Pfeiffer syndrome)
CCDS1298.1	NM_000141.3	FGFR2	fibroblast growth factor receptor 2 (bacteria-expressed kinase, keratinocyte growth factor receptor)
CCDS3353.1	NM_000142.2	FGFR3	fibroblast growth factor receptor 3 (achondroplasia, thanatophoric dwarfism)
CCDS4410.1	NM_002011.3	FGFR4	fibroblast growth factor receptor 4 isoform 1
CCDS305.1	NM_005248.2	FGR	Gardner-Rasheed feline sarcoma viral (v-fgr) oncogene homolog
CCDS9330.1	NM_002019.3	FLT1/VEGFR1	fms-related tyrosine kinase 1 (vascular endothelial growth factor/vascular permeability factor receptor)
CCDS31953.1	NM_004119.2	FLT3	fms-related tyrosine kinase 3
CCDS4457.1	NM_182925.3	FLT4/VEGFR3	fms-related tyrosine kinase 4
CCDS5103.1	NM_002031.2	FRK	fyn-related kinase
CCDS5094.1	NM_002037.3	FYN	FYN oncogene related to SRC, FGR, YES
CCDS33460.1	NM_002110.2	HCK	hemopoietic cell kinase
CCDS10378.1	NM_000875.3	IGF1R	insulin-like growth factor 1 receptor
CCDS12176.1	NM_000208.2	INSR	insulin receptor
CCDS1160.1	NM_014215.1	INSRR	insulin receptor-related receptor
CCDS4336.1	NM_005546.3	ITK	IL2-inducible T-cell kinase
N/A	NM_002227.2	JAK1	Janus kinase 1
CCDS6457.1	NM_004972.2	JAK2	Janus kinase 2
CCDS12366.1	NM_000215.2	JAK3	Janus kinase 3
CCDS3497.1	NM_002253.1	KDR/VEGFR2	kinase insert domain receptor (a type III receptor tyrosine kinase)
CCDS3496.1	NM_000222.2	KIT	v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog
CCDS359.1	NM_005356.3	LCK	lymphocyte-specific protein tyrosine kinase
CCDS10078.1	NM_206961.1	LTK	leukocyte tyrosine kinase
CCDS6162.1	NM_002350.2	LYN	v-yes-1 Yamaguchi sarcoma viral related oncogene homolog
CCDS12113.1	NM_002378.3	MATK	megakaryocyte-associated tyrosine kinase
CCDS2094.1	NM_006343.2	MERTK/MER	c-mer proto-oncogene tyrosine kinase
N/A	NM_000245.2	MET	met proto-oncogene (hepatocyte growth factor receptor)
CCDS2807.1	NM_002447.2	MST1R/RON	macrophage stimulating 1 receptor (c-met-related tyrosine kinase)
N/A	NM_005592.1	MUSK	muscle, skeletal, receptor tyrosine kinase
CCDS1161.1	NM_002529.3	NTRK1	neurotrophic tyrosine kinase, receptor, type 1
CCDS35053.1	NM_001007097.1	NTRK2	neurotrophic tyrosine kinase receptor type 2
CCDS32322.1	NM_001012338.1	NTRK3	neurotrophic tyrosine kinase receptor type 3
CCDS3495.1	NM_006206.3	PDGFRA	platelet-derived growth factor receptor alpha
CCDS4303.1	NM_002809.3	PDGFRB	platelet-derived growth factor receptor beta
CCDS4884.1	NM_002821.3	PTK7	PTK7 protein tyrosine kinase 7
CCDS6057.1	NM_004103.3	PYK2/PTK2B	PTK2B protein tyrosine kinase 2 beta
CCDS7200.1	NM_020975.4	RET	ret proto-oncogene
CCDS626.1	NM_005012.2	ROR1	receptor tyrosine kinase-like orphan receptor 1
CCDS6691.1	NM_004560.2	ROR2	receptor tyrosine kinase-like orphan receptor 2
CCDS5116.1	NM_002944.2	ROS1	v-ros UR2 sarcoma virus oncogene homolog 1 (avian)
N/A	NM_001005861.2	RYK	RYK receptor-like tyrosine kinase
CCDS13294.1	NM_005417.3	SRC	v-src sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog (avian)
CCDS13525.1	NM_080823.2	SRMS	src-related kinase lacking C-terminal regulatory tyrosine and N-terminal myristylation sites
CCDS6688.1	NM_003177.3	SYK	spleen tyrosine kinase
CCDS3481.1	NM_003215.2	TEC	tec protein tyrosine kinase
CCDS6519.1	NM_000459.2	TEK	TEK tyrosine kinase, endothelial (venous malformations, multiple cutaneous and mucosal)
CCDS482.1	NM_005424.2	TIE	tyrosine kinase with immunoglobulin-like and EGF-like domains 1
N/A	NM_003985.3	TNK1	tyrosine kinase, non-receptor, 1
CCDS3480.1	NM_003328.2	TXK	TXK tyrosine kinase
CCDS12236.1	NM_003331.3	TYK2	tyrosine kinase 2
CCDS10080.1	NM_006293.2	TYRO3	TYRO3 protein tyrosine kinase
CCDS11824.1	NM_005433.3	YES1	v-yes-1 Yamaguchi sarcoma viral oncogene homolog 1
CCDS33254.1	NM_001079.3	ZAP70	zeta-chain (TCR) associated protein kinase 70kDa

Table S2. Primers used for PCR amplification and sequencing of kinase domains

Gene and Exon Name	CCDS accession	Ref Seq accession	Forward Primer	Reverse Primer	Sequencing Primer (Forward)	Sequencing Primer (Reverse)
ABL1_Exon-4	CCDS3165.1	NM_007313.2	CTCTGTCTGTGGAGAGC	GGAATGATTAAGACGGAAAGTCA	TGTAAGACAGGCCAGT	CAGGAACAGCTATGACC
ABL1_Exon-5	CCDS3165.1	NM_007313.2	AGCTGTCATGAGCACTGTG	ACTTGAATTACGCAGGGAG	TGTAAGACAGGCCAGT	CAGGAACAGCTATGACC
ABL1_Exon-6	CCDS3165.1	NM_007313.2	ACTCTGAGGATTCAGGTCT	CCCGCAGGGAACAATGAGTA	TGTAAGACAGGCCAGT	CAGGAACAGCTATGACC
ABL1_Exon-7	CCDS3165.1	NM_007313.2	ATTTGGGATCTGAGGCTGT	GANGAGAAAGAGGAGCGAG	TGTAAGACAGGCCAGT	CAGGAACAGCTATGACC
ABL2_Exon-5	CCDS30947.1	NM_007314.2	GACCTCAAAATATCCCACTT	AGGGCCAGGAATCTGTATTA	TGTAAGACAGGCCAGT	CAGGAACAGCTATGACC
ABL2_Exon-6	CCDS30947.1	NM_007314.2	AGGAGAGAAAGGACAGAGA	TTCTTAATCTCTTTCAAGTTTGTG	TGTAAGACAGGCCAGT	CAGGAACAGCTATGACC
ABL2_Exon-7	CCDS30947.1	NM_007314.2	AAAAACCATTTGGATAGAAAG	GGACACCATTCCTGATTTTGT	TGTAAGACAGGCCAGT	CAGGAACAGCTATGACC
ABL2_Exon-8	CCDS30947.1	NM_007314.2	TTTCACCTTATCCCAAGAG	GCCATGTGCAAACTGTAGACA	TGTAAGACAGGCCAGT	CAGGAACAGCTATGACC
ABL2_Exon-9	CCDS30947.1	NM_007314.2	TTCAATCTAAACAACGAGAGG	TGGTCTATGTTATTTTCCTCAATTAC	TGTAAGACAGGCCAGT	CAGGAACAGCTATGACC
ACK1_Exon-4	CCDS33928.1	NM_005781.4	ACTGTGGATAGGCACACT	CATGCGTGTGGTCTTTCTT	TGTAAGACAGGCCAGT	CAGGAACAGCTATGACC
ACK1_Exon-5	CCDS33928.1	NM_005781.4	GTGATTTCCAGCAGCCAGC	ACTCCTAGAGTCCTCCAGCAGC	TGTAAGACAGGCCAGT	CAGGAACAGCTATGACC
ACK1_Exon-6	CCDS33928.1	NM_005781.4	CTCCCTGAGGCATACAGATAC	CADGGCTCACCAGAAATTT	TGTAAGACAGGCCAGT	CAGGAACAGCTATGACC
ACK1_Exon-7	CCDS33928.1	NM_005781.4	CCCTTACCTCTCCCTGGATG	GGGAGGCCGACGAAAGAGAG	TGTAAGACAGGCCAGT	CAGGAACAGCTATGACC
ALXK_Exon-21;ALXK_Exon-22	CCDS33172.1	NM_004303.4	GGGATTTATAGCCACACAGC	TCGTGATTTAGCTTGCATTTACT	TGTAAGACAGGCCAGT	CAGGAACAGCTATGACC
ALXK_Exon-23	CCDS33172.1	NM_004303.4	CCCCCTCTCAAGCTTAAAT	TCCTTCTTACCAGTTTCAAGTG	TGTAAGACAGGCCAGT	CAGGAACAGCTATGACC
ALXK_Exon-24	CCDS33172.1	NM_004303.4	ATCTCTAGCTCAAGTGTGTG	GCAAGCTCTCAAGCTCTCTCT	TGTAAGACAGGCCAGT	CAGGAACAGCTATGACC
ALXK_Exon-25	CCDS33172.1	NM_004303.4	AAGTTCCTCATAGCTGAA	AAGGCCAGATAGCTTCTTA	TGTAAGACAGGCCAGT	CAGGAACAGCTATGACC
ALXK_Exon-26	CCDS33172.1	NM_004303.4	TTGTGGGTTGATTTGATCTT	TGCATCTACTGAACTAAATGGTGTG	TGTAAGACAGGCCAGT	CAGGAACAGCTATGACC
ALXK_Exon-27	CCDS33172.1	NM_004303.4	CACTGAATGGCTCAACTT	GSAATGTAAAGCAGCAACT	TGTAAGACAGGCCAGT	CAGGAACAGCTATGACC
ALXK_Exon-28	CCDS33172.1	NM_004303.4	TTGTACTCTGGAGTGTACC	CTCTCTCTGGAGTGTGTGT	TGTAAGACAGGCCAGT	CAGGAACAGCTATGACC
AXL_Exon-13;AXL_Exon-14	CCDS12575.1	NM_021913.3	GGTGAAGTAGAGGGGTCT	CCCATTCGCTATGTGAAACA	TGTAAGACAGGCCAGT	CAGGAACAGCTATGACC
AXL_Exon-15	CCDS12575.1	NM_021913.3	CTGGAGACTCTGGGAAAC	CCATGTTCTTGCCTTGACTG	TGTAAGACAGGCCAGT	CAGGAACAGCTATGACC
AXL_Exon-16	CCDS12575.1	NM_021913.3	CTGTGTGAGTCCTGGTGA	GGTCTGTGAAAAGCTGTAC	TGTAAGACAGGCCAGT	CAGGAACAGCTATGACC
AXL_Exon-17	CCDS12575.1	NM_021913.3	CAGTCTACAATATTAGCTGACT	GGTCCCTGAAAGGCACTAC	TGTAAGACAGGCCAGT	CAGGAACAGCTATGACC
AXL_Exon-18	CCDS12575.1	NM_021913.3	GAAGCCCTTTGCCACTC	TGGCTGTCCACTTATATGAT	TGTAAGACAGGCCAGT	CAGGAACAGCTATGACC
AXL_Exon-19	CCDS12575.1	NM_021913.3	CTCCAGAGGATGGTTTGA	CTCAGGTTGTGAGGAGTAT	TGTAAGACAGGCCAGT	CAGGAACAGCTATGACC
AXL_Exon-20	CCDS12575.1	NM_021913.3	CAAGTGTCACTGACTG	CGACGATGACTGAGAGTAC	TGTAAGACAGGCCAGT	CAGGAACAGCTATGACC
BLK_Exon-10	CCDS5982.1	NM_001715.2	AAGCTTAGCCCTGTCTTC	AACTGTTTCTTCTGCTGAGACT	TGTAAGACAGGCCAGT	CAGGAACAGCTATGACC
BLK_Exon-11	CCDS5982.1	NM_001715.2	CTTGCTATGTCTGCTGGT	GAATCCACTATGGTGGAAAG	TGTAAGACAGGCCAGT	CAGGAACAGCTATGACC
BLK_Exon-12	CCDS5982.1	NM_001715.2	GAAGCCTAGCTGCTGGTGG	GTGATTTAGCTTTCTGGTCTT	TGTAAGACAGGCCAGT	CAGGAACAGCTATGACC
BLK_Exon-7	CCDS5982.1	NM_001715.2	GGCCAAAGCAAGGAAAGTA	GCACCTAGGCTCTGAAACT	TGTAAGACAGGCCAGT	CAGGAACAGCTATGACC
BLK_Exon-8	CCDS5982.1	NM_001715.2	GGACCTGAACGCAGGATG	CAGTGTAAAGTGTGCATGA	TGTAAGACAGGCCAGT	CAGGAACAGCTATGACC
BLK_Exon-9	CCDS5982.1	NM_001715.2	TGCTGAGAAGTGGCTTTGTA	CTGGGATGGGAAAGTCTACAG	TGTAAGACAGGCCAGT	CAGGAACAGCTATGACC
BMX_Exon-13	CCDS14168.1	NM_203281.2	GTCCATCACTGCTGAGCTG	GTCGCACTGCTGCTGAGTAC	TGTAAGACAGGCCAGT	CAGGAACAGCTATGACC
BMX_Exon-14	CCDS14168.1	NM_203281.2	TCGCCCAAAAGATATTGCT	GGTCTTTAGCACTAAGCCTGAC	TGTAAGACAGGCCAGT	CAGGAACAGCTATGACC
BMX_Exon-15	CCDS14168.1	NM_203281.2	TTTAGAGCACTTGGGGTGT	TGACAGACAAAGAGAGTAGCC	TGTAAGACAGGCCAGT	CAGGAACAGCTATGACC
BMX_Exon-16	CCDS14168.1	NM_203281.2	ACAAACCTTAGGAGCTCTG	ACTTTCATCCCTTCTGATG	TGTAAGACAGGCCAGT	CAGGAACAGCTATGACC
BMX_Exon-17	CCDS14168.1	NM_203281.2	TGTGATTTGTGTTGGTCTG	TTCAGGACTTCAGTCTTTGA	TGTAAGACAGGCCAGT	CAGGAACAGCTATGACC
BRK_Exon-4	CCDS13524.1	NM_005975.2	NTTGAAGGAGAACCCCTCG	AGGTCGCATTCTCTACTGG	TGTAAGACAGGCCAGT	CAGGAACAGCTATGACC
BRK_Exon-5	CCDS13524.1	NM_005975.2	GTCTGCATTTATCTCTCAC	AATGGAAGCCATTAATATGATCA	TGTAAGACAGGCCAGT	CAGGAACAGCTATGACC
BRK_Exon-6	CCDS13524.1	NM_005975.2	CTGCTGTTGGTCCCAATG	TGCTCTGTGTTTGGTGAATA	TGTAAGACAGGCCAGT	CAGGAACAGCTATGACC
BRK_Exon-7	CCDS13524.1	NM_005975.2	CAGGAATGCTGGATGTTG	CAGCAATGCTTGGATGATG	TGTAAGACAGGCCAGT	CAGGAACAGCTATGACC
BRK_Exon-7;BRK_Exon-8	CCDS13524.1	NM_005975.2	AGACACTCCAATTTGTAACC	AGGTCCTACCACCGTACT	TGTAAGACAGGCCAGT	CAGGAACAGCTATGACC
BTX_Exon-13	CCDS14482.1	NM_000061.1	CTGAGATGGTACCAACCTGA	ATAAGGATTTGGGGAGTTT	TGTAAGACAGGCCAGT	CAGGAACAGCTATGACC
BTX_Exon-14	CCDS14482.1	NM_000061.1	GGCAAGCACTATCTACTGG	GTCTGATCTGCTGATGAGAG	TGTAAGACAGGCCAGT	CAGGAACAGCTATGACC
BTX_Exon-15	CCDS14482.1	NM_000061.1	AGAAAGTCCGCAAAAGAG	CTCCCTTAATTCTTCCAGTATCA	TGTAAGACAGGCCAGT	CAGGAACAGCTATGACC
BTX_Exon-16	CCDS14482.1	NM_000061.1	AGCAAGACAATATCTGTTG	CCACCTTTTCACTCTTTGTT	TGTAAGACAGGCCAGT	CAGGAACAGCTATGACC
BTX_Exon-16;BTX_Exon-17	CCDS14482.1	NM_000061.1	GGCTGATGGCCACTTAAT	TTGGTAAAGTAGAATACACAGA	TGTAAGACAGGCCAGT	CAGGAACAGCTATGACC
CSF1R_Exon-11	CCDS4302.1	NM_005211.2	CTCTGTGGAGTCTGCTGAG	GTGAGATCTGCGAGCTATGAG	TGTAAGACAGGCCAGT	CAGGAACAGCTATGACC
CSF1R_Exon-13	CCDS4302.1	NM_005211.2	CCAG30ACTGGAGCAAGTAG	GTGAGCACTGGGTTTCTGTT	TGTAAGACAGGCCAGT	CAGGAACAGCTATGACC
CSF1R_Exon-14	CCDS4302.1	NM_005211.2	AACCTGTGGTGGCTACTG	CGCCAGCCACTGTGTTTTA	TGTAAGACAGGCCAGT	CAGGAACAGCTATGACC
CSF1R_Exon-15;CSF1R_Exon-16	CCDS4302.1	NM_005211.2	TCGCCAAATGACTCTTCATA	CTGCAAGTCCAGTGATGATGA	TGTAAGACAGGCCAGT	CAGGAACAGCTATGACC
CSF1R_Exon-16;CSF1R_Exon-17	CCDS4302.1	NM_005211.2	CTCAGGAAAGTGAAGTAG	TGCAGTCTTGTCTGATGATG	TGTAAGACAGGCCAGT	CAGGAACAGCTATGACC
CSF1R_Exon-17;CSF1R_Exon-18	CCDS4302.1	NM_005211.2	AGGGAAGGCAGGAGAGGAT	GGCCCTGGTGAAGATATGACA	TGTAAGACAGGCCAGT	CAGGAACAGCTATGACC
CSF1R_Exon-19	CCDS4302.1	NM_005211.2	TGTCTCCACTATGGGAGAG	TGCTGTACTTGTACCTCCCT	TGTAAGACAGGCCAGT	CAGGAACAGCTATGACC
CSF1R_Exon-20	CCDS4302.1	NM_005211.2	CTGTCGAGTCTGGTGTGTT	GTGAGTCCTTCTGAGAGT	TGTAAGACAGGCCAGT	CAGGAACAGCTATGACC
CSK_Exon-11;CSK_Exon-12	CCDS10289.1	NM_004383.1	CTACAGGCGTGGCAGGAT	AGGTCCGACAGTGTCTCAT	TGTAAGACAGGCCAGT	CAGGAACAGCTATGACC
CSK_Exon-12	CCDS10289.1	NM_004383.1	GCTCCGCGAAGCTGAT	CGGAGGCTCCCTAGAGAG	TGTAAGACAGGCCAGT	CAGGAACAGCTATGACC
CSK_Exon-9;CSK_Exon-7;CSK_Exon-8	CCDS10289.1	NM_004383.1	GATGAGTCTACCAGGATGAT	GTTTGGGGCAGTGGAAAG	TGTAAGACAGGCCAGT	CAGGAACAGCTATGACC
DDR1_Exon-12;DDR1_Exon-13	CCDS4690.1	NM_001954.4	CTGCAAGTCTGCTCTGATG	GATCCAGACTGCTAGCTTGA	TGTAAGACAGGCCAGT	CAGGAACAGCTATGACC
DDR1_Exon-12;DDR1_Exon-13;DDR1_Exon-14	CCDS4690.1	NM_001954.4	CGCTGAAATCTGGGAAGTGA	GTGCTCACTGGCTACTCTG	TGTAAGACAGGCCAGT	CAGGAACAGCTATGACC
DDR1_Exon-14	CCDS4690.1	NM_001954.4	ATCTTGGGGAGTAAAGC	CTGGTGGCAGTAGGAACT	TGTAAGACAGGCCAGT	CAGGAACAGCTATGACC
DDR2_Exon-11	CCDS1241.1	NM_006182.2	TTGTAACACATCTTCTTATTGG	CTTTGTCGAGGAGGTATGACA	TGTAAGACAGGCCAGT	CAGGAACAGCTATGACC
DDR2_Exon-12	CCDS1241.1	NM_006182.2	CAAAAGTTATCAAAGGAAACA	AGTCAAGTACTTGTATGGTCTT	TGTAAGACAGGCCAGT	CAGGAACAGCTATGACC
DDR2_Exon-14	CCDS1241.1	NM_006182.2	CTAGAGTAACTGGGATCTG	ATGAGTCTAATGAGTGGCTCCT	TGTAAGACAGGCCAGT	CAGGAACAGCTATGACC
DDR2_Exon-15	CCDS1241.1	NM_006182.2	TGTTCTTAATCTGACTGATG	AGATCAAACTCTGATGATG	TGTAAGACAGGCCAGT	CAGGAACAGCTATGACC
DDR2_Exon-16	CCDS1241.1	NM_006182.2	AGTGGCCAAAAGAAAGTCT	TATAGGATCAAGGGTATGAGG	TGTAAGACAGGCCAGT	CAGGAACAGCTATGACC
EGFR_Exon-18	CCDS5514.1	NM_005228.3	GGGTGCTCTGCTGTTGAT	TTTATAGACTGCACCCATCT	TGTAAGACAGGCCAGT	CAGGAACAGCTATGACC
EGFR_Exon-19	CCDS5514.1	NM_005228.3	CCDS5514.1	GGCTTTGCTTCCACCTGACT	TGTAAGACAGGCCAGT	CAGGAACAGCTATGACC
EGFR_Exon-20	CCDS5514.1	NM_005228.3	AGCCAGGGTCTCACCTCTCT	GGCTTATGAAGGGGACTTAT	TGTAAGACAGGCCAGT	CAGGAACAGCTATGACC
EGFR_Exon-21	CCDS5514.1	NM_005228.3	GGTGTCCAGAATCCCAAGC	CACCTCAATTCATGGCAACT	TGTAAGACAGGCCAGT	CAGGAACAGCTATGACC
EGFR_Exon-22	CCDS5514.1	NM_005228.3	TTCTCAAGTACAGAAGCATACC	TGGAGAGCTTCACATTAATCC	TGTAAGACAGGCCAGT	CAGGAACAGCTATGACC
EGFR_Exon-23	CCDS5514.1	NM_005228.3	AACTGATGTCTGCTGATGC	AGATCCACTTCCACTCTCT	TGTAAGACAGGCCAGT	CAGGAACAGCTATGACC
EGFR_Exon-24	CCDS5514.1	NM_005228.3	TGAGGGGAGCCACTATAA	GCTTGCACCACTCTCCACC	TGTAAGACAGGCCAGT	CAGGAACAGCTATGACC
EGFR_Exon-25	CCDS5514.1	NM_005228.3	CCTTCAATAATACCCTCAGA	TGGCTACTGGACACTCACAT	TGTAAGACAGGCCAGT	CAGGAACAGCTATGACC
EPHA1_Exon-11	CCDS5884.1	NM_005232.3	GAGTGGACTACTTGGAACTG	AGCTTCTGTGTTGACTCACT	TGTAAGACAGGCCAGT	CAGGAACAGCTATGACC
EPHA1_Exon-12;EPHA1_Exon-13	CCDS5884.1	NM_005232.3	GGGCTGCATTGTCTGCTG	CCGCACTAGCTTGGTCTTGT	TGTAAGACAGGCCAGT	CAGGAACAGCTATGACC
EPHA1_Exon-12;EPHA1_Exon-13;EPHA1_Exon-14	CCDS5884.1	NM_005232.3	ATTGTAGCCGCTGGGAAGTGA	CAGGAGAGTTGGGAAGTGA	TGTAAGACAGGCCAGT	CAGGAACAGCTATGACC
EPHA1_Exon-15	CCDS5884.1	NM_005232.3	CTGAGGTAGTCATCCAGATG	GCATCCACGCTCTGTATTCT	TGTAAGACAGGCCAGT	CAGGAACAGCTATGACC
EPHA1_Exon-16	CCDS5884.1	NM_005232.3	GCCAGCACTACAGAAATAGA	AGATCCACTTACAGTCACTA	TGTAAGACAGGCCAGT	CAGGAACAGCTATGACC
EPHA2_Exon-10;EPHA2_Exon-11	CCDS169.1	NM_004431.2	AGGCGCCTGAGTGTG	TCTCCAGTCAAGTGAGAGC	TGTAAGACAGGCCAGT	CAGGAACAGCTATGACC
EPHA2_Exon-10;EPHA2_Exon-11	CCDS169.1	NM_004431.2	CAGCTCGCTCTCTCTGTTG	GACCAAGTAGGGCCAGAG	TGTAAGACAGGCCAGT	CAGGAACAGCTATGACC
EPHA2_Exon-12;EPHA2_Exon-13	CCDS169.1	NM_004431.2	GTCGCGCACTCTTCACTG	CATACCTCTGCCACTCTCT	TGTAAGACAGGCCAGT	CAGGAACAGCTATGACC
EPHA2_Exon-12;EPHA2_Exon-13;EPHA2_Exon-14	CCDS169.1	NM_004431.2	CAGCGGATGGGGACTCTG	CCTACAGACAGCCATATGA	TGTAAGACAGGCCAGT	CAGGAACAGCTATGACC
EPHA2_Exon-15	CCDS169.1	NM_004431.2	TTCTCTTACAATAAGGATTA	AAAAGTCCCTCCAGTGA	TGTAAGACAGGCCAGT	CAGGAACAGCTATGACC
EPHA3_Exon-10	CCDS2922.1	NM_005233.5	AACTGAAGTTGGTGCAGCT	GTCCAGCAGGCTAAATAGG	TGTAAGACAGGCCAGT	CAGGAACAGCTATGACC
EPHA3_Exon-11	CCDS2922.1	NM_005233.5	TCACAAGTCTATTCTCAACA	CCCCAATCTTCTCTTAACT	TGTAAGACAGGCCAGT	CAGGAACAGCTATGACC
EPHA3_Exon-12	CCDS2922.1	NM_005233.5	ATTGGTACTGGGCTTGT	GTTTGGAAGTAGAGTGGGCT	TGTAAGACAGGCCAGT	CAGGAACAGCTATGACC
EPHA3_Exon-13	CCDS2922.1	NM_005233.5	CCACTATTCTTGTGTTGATG	GTCCTTAGATTCTCAACTCTGTA	TGTAAGACAGGCCAGT	CAGGAACAGCTATGACC
EPHA3_Exon-14	CCDS2922.1	NM_005233.5	GACTATTCATTTCAGAGCA	GGCTTTCAATGTTGGTCTG	TGTAAGACAGGCCAGT	CAGGAACAGCTATGACC
EPHA3_Exon-15	CCDS2922.1	NM_005233.5	CAGTTTGTTTATTGAGCAAC	AAGCCTGAATGAGGTAAGATG	TGTAAGACAGGCCAGT	CAGGAACAGCTATGACC
EPHA4_Exon-10	CCDS2447.1	NM_004438.3	TGATTTCAAGTTGCTAAATG	AGGCAAGGAGACTATGAGA	TGTAAGACAGGCCAGT	CAGGAACAGCTATGACC
EPHA4_Exon-11	CCDS2447.1	NM_004438.3	ACACAGCTGCCTGGAGTAG	TTATTCTTAGAGAAACTTATGGA	TGTAAGACAGGCCAGT	CAGGAACAGCTATGACC
EPHA4_Exon-12	CCDS2447.1	NM_004438.3	CTCCAAGCTCCCACTADAG	ATTGGCTTAGTGCCTTTAGC	TGTAAGACAGGCCAGT	CAGGAACAGCTATGACC
EPHA4_Exon-13	CCDS2447.1	NM_004438.3	TTTGTCTTCTATTTGCTGCT	CTGTTGGAGCCTAGATCTAT	TGTAAGACAGGCCAGT	CAGGAACAGCTATGACC
EPHA4_Exon-14	CCDS2447.1	NM_004438.3	GGTGTAAATGTGAAGTACCTG	TAGACTGCTCTCTTGTG	TGTAAGACAGGCCAGT	CAGGAACAGCTATGACC
EPHA5_Exon-11	CCDS3514.1	NM_182472.1	ACTGATTTTGAAGTCTGGT	AGGCGGTCCCAAAACT	TGTAAGACAGGCCAGT	CAGGAACAGCTATGACC
EPHA5_Exon-12	CCDS3514.1	NM_182472.1	TTTGTGTTTAAAGTGAATG	ACTAGTATTGCACTGCTG	TGTAAGACAGGCCAGT	CAGGAACAGCTATGACC
EPHA5_Exon-14	CCDS3514.1	NM_182472.1	AATTCATAGCAAAAGTATA	AAAGTTTTGTAAGTAGATAGAGA	TGTAAGACAGGCCAGT	CAGGAACAGCTATGACC
EPHA5_Exon-15	CCDS3514.1	NM_182472.1	CTTTGTTGGAGGATGCTT	TAGCCAGGCAAGTACTAGGT	TGTAAGACAGGCCAGT	CAGGAACAGCTATGACC
EPHA6_Exon-10	N/A	NM_00108048.2	GGGGAGGAGGAGGAGAG	TGACCTAAACTACATTGAACAA	TGTAAGACAGGCCAGT	CAGGAACAGCTATGACC
EPHA6_Exon-12	N/A	NM_00108048.2	TCGACTCCAAATTTAGGATG	ATGTTAGGAAATGTTGCAAGT	TGTAAGACAGGCCAGT	CAGGAACAGCTATGACC
EPHA6_Exon-13	N/A	NM_00108048.2	TGCTTCAAGCCCTTTAATGTA	ATTCAGGTTGGGAAGTGTGCA	TGTAAGACAGGCCAGT	CAGGAACAGCTATGACC
EPHA6_Exon-14	N/A	NM_00108048.2	TTGTAATATTGCTCTTATGA	CGATCAGTTAAGGATTTCA	TGTAAGACAGGCCAGT	CAGGAACAGCTATGACC
EPHA6_Exon-15	N/A	NM_00108048.2	GGTCTTTCATTGCTTCACT	TGACATGAGCTTAAAGCTGA	TGTAAGACAGGCCAGT	CAGGAACAGCTATGACC
EPHA7_Exon-11	CCDS5031.1	NM_004440.2	CATAACCAAGTACAGCTCGC	AGGTCAAGGTTTGGCAAAAC	TGTAAGACAGGCCAGT	CAGGAACAGCTATGACC
EPHA7_Exon-12	CCDS5031.1	NM_004440.2	TCAGAGTATTTTCAACCTGAT	AGGAAAGGCTTCAAGTAGAAG	TGTAAGACAGGCCAGT	CAGGAACAGCTATGACC
EPHA7_Exon-13	CCDS5031.1	NM_004440.2	AAAAAGTCTCAGAGTCTGAAC	AAATGTGTCATTGGAGAG	TGTAAGACAGGCCAGT	CAGGAACAGCTATGACC
EPHA7_Exon-14						

Table with 6 columns: Locus ID, Gene Name, RefSeq ID, Gene Type, and Coordinates. The table lists various gene models and their genomic locations across chromosomes 1 through 22, X, and Y. It includes entries for genes like FYN, HCK, IGF1R, INSRR, ITK, JAK, KDR, KIT, LCK, LYN, and MERTK, detailing their exon-intron structure and corresponding RefSeq identifiers.

MSTR1_Exon-9 CDS2807.1 NM_02447.2 GAGCTCAGAACTGGCTTACCAT ...

TKX1_Exon-6	N/A	NM_003985.3	AAAGAGGACTTTTGTGAAGAGTG	TGTCAACGACTGCAACTG	TGTAACAGCAGGCCAGT	CAGGAACAGCTATGACC
TKX_Exon-10	CCDS3480.1	NM_003328.2	GACATTGGAGCTTGGAAAGTG	TCCCAGGTCTAGTTTTGGTAGG	TGTAACAGCAGGCCAGT	CAGGAACAGCTATGACC
TKX_Exon-11	CCDS3480.1	NM_003328.2	TAAATTGGACCATATCTTACCA	AGTCACTCTTTCCTCCCTCTTG	TGTAACAGCAGGCCAGT	CAGGAACAGCTATGACC
TKX_Exon-13	CCDS3480.1	NM_003328.2	ACGATGGGGATGTTGGTAGAA	GCAGGCTCTTTGTAGAGTTAKGA	TGTAACAGCAGGCCAGT	CAGGAACAGCTATGACC
TKX_Exon-14	CCDS3480.1	NM_003328.2	TGCAAGAACCACATCTCAACAA	AAAAAGAAAGAAATCTACTGG	TGTAACAGCAGGCCAGT	CAGGAACAGCTATGACC
TKX_Exon-15	CCDS3480.1	NM_003328.2	GTGCAATTCCTCTCACACATA	TCACCCCTCACTCACTG	TGTAACAGCAGGCCAGT	CAGGAACAGCTATGACC
TYK2_Exon-10;TYK2_Exon-11	CCDS12236.1	NM_003331.3	GGTCCCTGCTACCTCTCTG	CTACCCCTGATCCTCACAG	TGTAACAGCAGGCCAGT	CAGGAACAGCTATGACC
TYK2_Exon-10;TYK2_Exon-11;TYK2_Exon-12	CCDS12236.1	NM_003331.3	GGGATCAGAGTACAGGTGAG	GGGTTGACCAAGAGGATCA	TGTAACAGCAGGCCAGT	CAGGAACAGCTATGACC
TYK2_Exon-10;TYK2_Exon-11;TYK2_Exon-12	CCDS12236.1	NM_003331.3	AGGCTGGCTGTCTGTAGAA	GGGTTGACCAAGAGGATCA	TGTAACAGCAGGCCAGT	CAGGAACAGCTATGACC
TYK2_Exon-14;TYK2_Exon-15	CCDS12236.1	NM_003331.3	TCAAAGTCTCTTACTTGGCTCTG	ATAGTCAAGTTGCTCTTTCACA	TGTAACAGCAGGCCAGT	CAGGAACAGCTATGACC
TYK2_Exon-14;TYK2_Exon-15	CCDS12236.1	NM_003331.3	CTGCTGGTGGCCAGAGAGA	ATAGTCAAGTTGCTCTTTCACA	TGTAACAGCAGGCCAGT	CAGGAACAGCTATGACC
TYK2_Exon-16	CCDS12236.1	NM_003331.3	CTTATGAATGCCACTGGAAGAA	GCCCAGAGAGGTTTTATCTA	TGTAACAGCAGGCCAGT	CAGGAACAGCTATGACC
TYK2_Exon-17;TYK2_Exon-18	CCDS12236.1	NM_003331.3	GTACTGGGAGCCGGGATCG	CTGCTGGGAGGAGGATCG	TGTAACAGCAGGCCAGT	CAGGAACAGCTATGACC
TYK2_Exon-17;TYK2_Exon-18	CCDS12236.1	NM_003331.3	CTGCCCTTGGAGGGTTTCAC	CCTCCCAACAGGTTGTCAGT	TGTAACAGCAGGCCAGT	CAGGAACAGCTATGACC
TYK2_Exon-18;TYK2_Exon-19	CCDS12236.1	NM_003331.3	GTTGGGAGGTGAGTCAAG	CAGGAGAGTATGAACTACA	TGTAACAGCAGGCCAGT	CAGGAACAGCTATGACC
TYK2_Exon-19;TYK2_Exon-20	CCDS12236.1	NM_003331.3	CTTCACTGGGATCATGCCCTAT	GCTCTCGCCAGCAGAT	TGTAACAGCAGGCCAGT	CAGGAACAGCTATGACC
TYK2_Exon-20;TYK2_Exon-21	CCDS12236.1	NM_003331.3	ACCCGGAAGACCAGCAT	CGCCCACTGAAACTCAC	TGTAACAGCAGGCCAGT	CAGGAACAGCTATGACC
TYK2_Exon-22;TYK2_Exon-23	CCDS12236.1	NM_003331.3	CCTCTCCACAGCAGCATAGT	CAAACACCTGACTCACCTTA	TGTAACAGCAGGCCAGT	CAGGAACAGCTATGACC
TYRO3_Exon-12;TYRO3_Exon-13	CCDS10080.1	NM_006293.2	ACAAATCGCTGTGTGGAGTT	AGGCTACAGCTATCCCACT	TGTAACAGCAGGCCAGT	CAGGAACAGCTATGACC
TYRO3_Exon-13	CCDS10080.1	NM_006293.2	GGATGTTGTGGGGAATGTT	AGGCTACAGCTATCCCACT	TGTAACAGCAGGCCAGT	CAGGAACAGCTATGACC
TYRO3_Exon-14	CCDS10080.1	NM_006293.2	TTCAACACATAAACCACAA	TCTTATGTGGAGACTTTG	TGTAACAGCAGGCCAGT	CAGGAACAGCTATGACC
TYRO3_Exon-15;TYRO3_Exon-16	CCDS10080.1	NM_006293.2	GGATGCCCAAGCAGGATG	CTGGAGGGTATGTTCTAGTG	TGTAACAGCAGGCCAGT	CAGGAACAGCTATGACC
TYRO3_Exon-16;TYRO3_Exon-17	CCDS10080.1	NM_006293.2	GTCTCCAGCCCTCCTTA	CTGCTCACAGCTCACTCTG	TGTAACAGCAGGCCAGT	CAGGAACAGCTATGACC
TYRO3_Exon-17;TYRO3_Exon-18	CCDS10080.1	NM_006293.2	GGTAGCTTGGAGCAAGATG	CCATCAGCCAAACTCCAGAT	TGTAACAGCAGGCCAGT	CAGGAACAGCTATGACC
TYRO3_Exon-18	CCDS10080.1	NM_006293.2	CAGGACACCTAGTGACGCTGT	CAGTTCCTCTTCCAGGAT	TGTAACAGCAGGCCAGT	CAGGAACAGCTATGACC
TYRO3_Exon-19	CCDS10080.1	NM_006293.2	AACCTCGGGCTCAAATACC	GCACAGCTTGGGAGACTAC	TGTAACAGCAGGCCAGT	CAGGAACAGCTATGACC
YES1_Exon-10	CCDS11824.1	NM_005433.3	TATCTCATGTCTCACCTGTC	AGCTATTAGGTGCCAGCTGACTT	TGTAACAGCAGGCCAGT	CAGGAACAGCTATGACC
YES1_Exon-11	CCDS11824.1	NM_005433.3	TTGTTGGACCTGAAATACG	TAATCAATGGGTTGGCTTTT	TGTAACAGCAGGCCAGT	CAGGAACAGCTATGACC
YES1_Exon-6	CCDS11824.1	NM_005433.3	TTTTAAAGGATTTAGACCAACTTCA	CCATCTGCTCAGCTTCTCTTA	TGTAACAGCAGGCCAGT	CAGGAACAGCTATGACC
YES1_Exon-6;YES1_Exon-7	CCDS11824.1	NM_005433.3	ACAAAGTGTCAAGTTTCTCTATCC	AGAAGTCTGATGTTTATCG	TGTAACAGCAGGCCAGT	CAGGAACAGCTATGACC
YES1_Exon-8	CCDS11824.1	NM_005433.3	TCCACCAATTCACACACATAC	CCGTAATCAGACTTCTAGCCTTTT	TGTAACAGCAGGCCAGT	CAGGAACAGCTATGACC
YES1_Exon-9	CCDS11824.1	NM_005433.3	AGCTAAACAAATCTTATCTGGAAA	AAATTAATGGGATTTAGGTTGG	TGTAACAGCAGGCCAGT	CAGGAACAGCTATGACC
ZAP70_Exon-12	CCDS33254.1	NM_001079.3	CTCTCAGCCAGCAGTCTG	CTAGCTGCCCCGAAAG	TGTAACAGCAGGCCAGT	CAGGAACAGCTATGACC
ZAP70_Exon-7	CCDS33254.1	NM_001079.3	GTGCGAGAACACAGCATG	ATCGCAAAAGAAATCCAAAGT	TGTAACAGCAGGCCAGT	CAGGAACAGCTATGACC
ZAP70_Exon-8	CCDS33254.1	NM_001079.3	CGTGGTGGCAGCATGACT	AATGGTGACTGAGGTTAGC	TGTAACAGCAGGCCAGT	CAGGAACAGCTATGACC
ZAP70_Exon-9;ZAP70_Exon-10	CCDS33254.1	NM_001079.3	GTGTGGTGTGCTCAAGCC	GTGAGCCCTAGCTCCAGAC	TGTAACAGCAGGCCAGT	CAGGAACAGCTATGACC
ZAP70_Exon-9;ZAP70_Exon-10;ZAP70_Exon-11	CCDS33254.1	NM_001079.3	CTACGCCAAGTACGCGACTTT	ACTGGAGGACAGCAAC	TGTAACAGCAGGCCAGT	CAGGAACAGCTATGACC

PTK7-20	CCDS4884.1	NM_02821.3	GTA AACGACGGCCAGTTC AAGTCC ACAAAGTTG	AGACCTCAGCAATGCCTGTTG	GTA AACGACGGCCAGT
ROR2-1	CCDS6691.1	NM_004560.2	GTA AACGACGGCCAGTGG ACGCATCGTAGAAAGGG	GCTTATTGTA ACCAGCCCGAG	GTA AACGACGGCCAGT
ROR2-2	CCDS6691.1	NM_004560.2	GTA AACGACGGCCAGTCCC GATTTGCTATTCTTGTG	AAACACAGGAATCAAGGTGGC	GTA AACGACGGCCAGT
ROR2-3	CCDS6691.1	NM_004560.2	GTA AACGACGGCCAGTTCCTTGG AAGAGTTCATAGC	TGCTGACTGGTGTGTTCAG	GTA AACGACGGCCAGT
ROR2-4	CCDS6691.1	NM_004560.2	GTA AACGACGGCCAGTCTTCCCTGTGTGGTGTTC	CAAAATCGGCAAGACATGAG	GTA AACGACGGCCAGT
ROR2-5	CCDS6691.1	NM_004560.2	AATTGGATCGCAAGATG	GTA AACGACGGCCAGTCCC ACTGACCATGCCATTAAAC	GTA AACGACGGCCAGT
ROR2-6	CCDS6691.1	NM_004560.2	GTA AACGACGGCCAGTGTGG GCACTGGGATGC	CCTGGGCTTCA CCGACAC	GTA AACGACGGCCAGT
ROR2-7	CCDS6691.1	NM_004560.2	GTA AACGACGGCCAGTATTTGG GCTGGGACTTC	GTCAGGACAGAAAGCCCTC	GTA AACGACGGCCAGT
ROR2-8	CCDS6691.1	NM_004560.2	GTA AACGACGGCCAGTAGGTGG AAGTGGTGGTAG	GCAGTGAATCCCAACAGC	GTA AACGACGGCCAGT
ROR2-9	CCDS6691.1	NM_004560.2	GTA AACGACGGCCAGTAGGAAGTCA GTGTGCCACG	AGCTGAAGATCATGCTCAGGG	GTA AACGACGGCCAGT
ROR2-9	CCDS6691.1	NM_004560.2	GACCGGTTGGGAAAGTCTAC	GTA AACGACGGCCAGTCA CACCGTAGGACAGATGTC	GTA AACGACGGCCAGT
ROR2-9	CCDS6691.1	NM_004560.2	AGTACCTATCCAGCCACCATG	GTA AACGACGGCCAGTGTG TCTCACATTGCTCACTGG	GTA AACGACGGCCAGT
ROR2-9	CCDS6691.1	NM_004560.2	GTA AACGACGGCCAGTGAAGTCTCCATCGACTCAG	ATCTGCATTGGGATCTGCAC	GTA AACGACGGCCAGT
ROR2-9	CCDS6691.1	NM_004560.2	CCAGTGAGCAATGTGAGCAAC	GTA AACGACGGCCAGTCTCAAAGGTGACTGAGGTC	GTA AACGACGGCCAGT
TIE1-1	CCDS482.1	NM_005424.2	GTA AACGACGGCCAGTAGCCACCTATTCTCTTCC	AATTGATCCTCCCATCTCAGC	GTA AACGACGGCCAGT
TIE1-2	CCDS482.1	NM_005424.2	GTA AACGACGGCCAGTAGTAAGACCAGAGGCTGGG	GACCTTGTCTGGAAGCAGGTG	GTA AACGACGGCCAGT
TIE1-3	CCDS482.1	NM_005424.2	ACAGCCCTGGAGGTGAGTTAG	GTA AACGACGGCCAGTCTACAGGAGAGGCCCTGG	GTA AACGACGGCCAGT
TIE1-4	CCDS482.1	NM_005424.2	AGCTGAGCAGAGGTGGACAG	GTA AACGACGGCCAGTCTG GAGGAGGTTGTTCTCAGC	GTA AACGACGGCCAGT
TIE1-5	CCDS482.1	NM_005424.2	GTA AACGACGGCCAGTGCCTATGGGTACTCTCTGTG	CACCCACATGTTCTAGGGTC	GTA AACGACGGCCAGT
TIE1-6	CCDS482.1	NM_005424.2	GACCCTAGAACCTGTGGGTG	GTA AACGACGGCCAGTAA GTCAGAGGCAGAGTGGAGG	GTA AACGACGGCCAGT
TIE1-7	CCDS482.1	NM_005424.2	GTA AACGACGGCCAGTCCAGTCTCTATCCTCAGCC	AGAGCTCCCTGTCCATCAGAC	GTA AACGACGGCCAGT
TIE1-8	CCDS482.1	NM_005424.2	GTA AACGACGGCCAGTCTCCACTGAA AACAAGAACAG	CTGACCTCATGTGAGCAATGG	GTA AACGACGGCCAGT
TIE1-9	CCDS482.1	NM_005424.2	GTA AACGACGGCCAGTACAGTCCAGAGGCACACCTG	AGTATCTCCAGCTGAGCAGC	GTA AACGACGGCCAGT
TIE1-10	CCDS482.1	NM_005424.2	CCAGCTTGA AACAAGATGC	GTA AACGACGGCCAGTCTA GAGCTGGCATGCTCCC	GTA AACGACGGCCAGT
TIE1-11	CCDS482.1	NM_005424.2	GTA AACGACGGCCAGTGTGAGTGG AAGAGCTGGG	CAAGGAAGAACACCTCCAGTG	GTA AACGACGGCCAGT
TIE1-12	CCDS482.1	NM_005424.2	GTA AACGACGGCCAGTGTCTTCTTGTCTACTGGG	CCTCCGCTGTCTCTAGTGC	GTA AACGACGGCCAGT
TIE1-13	CCDS482.1	NM_005424.2	GTA AACGACGGCCAGTCTAGAGCAGATGTGTCCAGCC	TGTGGAGGAGAGCGCTGC	GTA AACGACGGCCAGT
TIE1-14	CCDS482.1	NM_005424.2	GTA AACGACGGCCAGTGGATCTTCACTCTCCCTC	CACACAAGGTGTACAAGTATTG	GTA AACGACGGCCAGT
TIE1-15	CCDS482.1	NM_005424.2	GTA AACGACGGCCAGTTGACACTGAAACCTCCTCTGTG	GTCAAATGCTGGAGGAAGCC	GTA AACGACGGCCAGT
TIE1-16	CCDS482.1	NM_005424.2	GTA AACGACGGCCAGTCTTTGCTCCAAATCCCAAG	GATGAAGGAGGATCAAGGGTG	GTA AACGACGGCCAGT
TIE1-17	CCDS482.1	NM_005424.2	GTA AACGACGGCCAGTATCCCTGTCTGTACCATCGG	GGCTGACTTCTCCACTGACAC	GTA AACGACGGCCAGT
TIE1-18	CCDS482.1	NM_005424.2	CGAAGACTGACTCTTACTGGC	GTA AACGACGGCCAGTCCC TAGGAGAAATGGGTTTG	GTA AACGACGGCCAGT
TIE1-19	CCDS482.1	NM_005424.2	AGTCTCATTCAACCCCTCACCC	GTA AACGACGGCCAGTCA CCTGTGTCCACCTTGGAAC	GTA AACGACGGCCAGT
TIE1-20	CCDS482.1	NM_005424.2	GTA AACGACGGCCAGTGGCCAAAGCCAGATACTTAC	ACACTTCACTGTCCAGATTTGG	GTA AACGACGGCCAGT
TIE1-21	CCDS482.1	NM_005424.2	GTA AACGACGGCCAGTGGGAGATAGTGAGCCTGGTG	CTAGCTGTAGCCCAATCTGGG	GTA AACGACGGCCAGT
TIE1-22	CCDS482.1	NM_005424.2	GTA AACGACGGCCAGTCA GCTTTGATCCTGTGACC	GCCTGGTGTCAAACCAAGTGAAG	GTA AACGACGGCCAGT
TIE1-23	CCDS482.1	NM_005424.2	GTA AACGACGGCCAGTATGGAAGTCCAGGAGCTTGAG	CACCTACAAGCATGGGAACC	GTA AACGACGGCCAGT

#The primer pair did not meet our quality criteria that ≥90% of bases in the target region have a Phred quality score of at least 20 in three quarters of the tumor samples analyzed.

Table S4. Characteristics of melanoma patients with PTK mutations

Sample	Patient Age (years)*	Patient Gender	Tumor Source	Matched normal source
1T	29	F	Lung	Blood
2T	30	M	Pectoral muscle	Blood
3T	18	M	Forehead, subcutaneous	Blood
4T	33	F	Supraclavicular, soft tissue	Blood
4T	34	F	Lung	Blood
5T	47	M	External iliac soft tissue	Blood
6T	42	M	Neck, soft tissue	Blood
7T	53	M	Stomach	Blood
8T	61	M	Inguinal soft tissue	Blood
9T	62	M	Back, subcutaneous	Blood
10T	55	M	Axillary soft tissue	Blood
12T	53	M	Upper arm, subcutaneous	Blood
13T	49	M	Chest wall, subcutaneous	Blood
15T	39	M	Thigh, subcutaneous	Blood
16T	62	M	Lung	Blood
17T	33	M	Shoulder, subcutaneous	Blood
18T	55	M	Clavicle, soft tissue	Blood
19T	49	M	Scapula, subcutaneous	Blood
20T	58	F	Axillary soft tissue	Blood
21T	59	M	Omentum	Blood
22T	51	M	Chest wall, subcutaneous	Blood
23T	44	M	Lung	Blood
24T	49	M	Axillary soft tissue	Blood
26T	48	F	Lung	Blood
28T	28	F	Axillary soft tissue	Blood
29T	51	M	Inguinal soft tissue	Blood
30T	53	F	Lung	Blood
31T	49	F	Thigh, subcutaneous	Blood
32T	58	M	Omentum	Blood
33T	33	M	Chest wall subcutaneous, & pleura **	Blood
34T	31	M	Shoulder, subcutaneous	Blood
35T	23	F	Thigh, subcutaneous	Blood
36T	25	M	Thigh, subcutaneous	Blood
37T	38	F	Omentum	Blood
38T	27	M	Skull	Blood
39T	56	M	Mesentery	Blood
41T	45	M	Neck, soft tissue	Blood
43T	19	F	Popliteal soft tissue	Blood
44T	56	M	Lung	Blood
45T	48	M	Mediastinum	Blood
49T	43	M	Thigh, subcutaneous	Blood
50T	49	F	Inguinal soft tissue	Blood
51T	50	F	Adnexa	Blood
52T	39	F	Lung	Blood
54T	27	M	Subcutaneous	Blood
55T	60	M	Lung	Blood
56T	52	M	Lung	Blood
58T	46	F	Hip, subcutaneous	Blood
59T	64	F	Abdomen, subcutaneous	Blood
60T	46	M	Flank, subcutaneous	Blood
62T	58	F	Thigh, subcutaneous	Blood
63T	30	M	Jejunum	Blood
64T	32	F	Ovary	Blood
68T	49	M	Lung	Blood
69T	36	M	Axillary soft tissue	Blood
71T	67	M	Lung	Blood
72T	53	M	Liver	Blood
73T	45	F	Breast	Blood
74T	40	F	Lower extremity, subcutaneous	Blood
76T	40	M	Neck, soft tissue	Blood
77T	39	M	Lung	Blood
78T	27	F	Lung	Blood
79T	53	M	Supraclavicular, soft tissue	Blood
80T	36	F	Popliteal soft tissue	Blood
81T	60	F	Upper arm, subcutaneous	Blood
83T	33	F	Back, subcutaneous	Blood
84T	60	F	Thigh, subcutaneous	Blood
85T	44	M	Chest wall, subcutaneous	Blood
86T	42	F	Liver	Blood
87T	27	M	Small bowel & mesentery **	Blood
88T	37	F	Chest wall, subcutaneous	Blood
90T	19	M	Neck, soft tissue	Blood
91T	55	F	Subcostal soft tissue	Blood
92T	37	F	Femur	Blood
93T	42	F	Axillary soft tissue	Blood
94T	44	M	Adrenal gland	Blood
95T	58	F	Inguinal soft tissue	Blood
96T	49	M	Inguinal soft tissue	Blood
99T	57	M	Liver	Blood

* Patient's age when tumor was surgically removed. ** Cell line generated by cells mixed from 2 tumors resected during the patient's surgery. Abbreviations: F, female; M, male.

Table S5. Mutations Identified in RAF and RAS isoforms in melanoma samples containing ERBB4 mutations

Sample	ERBB4	BRAF	NRAS	ARAF	CRAF	HRAS	KRAS
7T	E452K	wt	Q61R	wt	wt	wt	wt
12T	E563K	wt	Q61Q/R	wt	wt	wt	wt
17T	E317K	wt	Q61Q/K	wt	wt	wt	wt
31T	wt	wt	wt	wt	wt	wt	wt
34T	R491K	V600V/E	wt	wt	T362T/A	wt	wt
39T	wt	wt	wt	wt	wt	wt	wt
49T	R393R/W	V600V/E	wt	wt	wt	wt	wt
55T	E452K	V600V/E	wt	P216S, P254L	wt	wt	wt
56T	R544R/W	V600V/E	wt	wt	wt	wt	wt
63T	E542K, E872K	wt	Q61Q/K	wt	wt	wt	wt
68T	Splice Site / LOH	V600V/E	wt	wt	wt	wt	wt
71T	L39L/F, S1246S/N	V600V/M, V600V/E	wt	wt	wt	wt	wt
86T	E836E/K	V600V/E	wt	wt	wt	wt	wt
93T	wt	wt	wt	A345A/G	wt	wt	wt

Table S6. Primers used for PCR amplification and sequencing of RAS and Raf isoforms

Gene and Exon Name	Forward Primer	Reverse Primer	Sequencing Primer
ARAF-1	TGAGCAGGATCTCTGGACTG	GTA AACGACGGCCAGTCAGCTGATGTTCCCATCCTTC	GTA AACGACGGCCAGT
ARAF-2	GTCATGGAAAGCGAATGGC	GTA AACGACGGCCAGTCAGAGGAATCAAAATGACTGAGG	GTA AACGACGGCCAGT
ARAF-3	GTA AACGACGGCCAGTTATCCCTCTGAGCCTGTTTCC	AGCAGGGAAGTTTGAGACTG	GTA AACGACGGCCAGT
ARAF-4	GTA AACGACGGCCAGTACCCAACTCCCACTCATT	CACGGGTCACTGCTGTGAAG	GTA AACGACGGCCAGT
ARAF-5	AGTACCAACGCCCAACAGT	GTA AACGACGGCCAGTGAGAAATGAGGTGACTTGCC	GTA AACGACGGCCAGT
ARAF-6	CAATTCGATGTTTATGGCTGG	GTA AACGACGGCCAGTCATCAGTGTGAACTCTGGC	GTA AACGACGGCCAGT
ARAF-7	GTA AACGACGGCCAGTCAAGCTCCATATGTCAGCAC	CTGGTGAATGTTGGG	GTA AACGACGGCCAGT
ARAF-8	CCAGAGTTTCAGCACTGATGG	GTA AACGACGGCCAGTCCAGATGGTGGCATCTAAG	GTA AACGACGGCCAGT
ARAF-9	GTA AACGACGGCCAGTGAAGAGTGGTATGCTCGAGGG	ATGTCCAGGAAGCACTCCAAG	GTA AACGACGGCCAGT
ARAF-10	GTA AACGACGGCCAGTGAACAGTGCCTCCTGATG	TCTCGTGGATGATGTTCTTG	GTA AACGACGGCCAGT
ARAF-11	GGATTTGCCATCATCACAG	GTA AACGACGGCCAGTCCCTGTAATTCAGAAACCC	GTA AACGACGGCCAGT
ARAF-12	GTA AACGACGGCCAGTCAAGGTTGTGGATGTTTGGC	GTGGACATGAGGAGTCCAG	GTA AACGACGGCCAGT
ARAF-13	GTGTGGGTGCTGTGAGTTG	GTA AACGACGGCCAGTGGCATTATCAGTGCAAAAGG	GTA AACGACGGCCAGT
ARAF-14	GTA AACGACGGCCAGTGCAGAGAAATCCTCCCAAGTC	TCACATCTGCCTCATCTCAG	GTA AACGACGGCCAGT
ARAF-15 ^a	GTGTGTTTCCACATGAGGC	GTA AACGACGGCCAGTGGCAGAGCAACATGTTG	GTA AACGACGGCCAGT
BRAF-1	GTA AACGACGGCCAGTAGCTCTCGCCTCCCTTC	AAGTGGCTGAGGGCATC	GTA AACGACGGCCAGT
BRAF-2	GTA AACGACGGCCAGTGAACAACTGGCAGTACTGTG	TCTCTTCCAAATCTATTCCTAATCC	GTA AACGACGGCCAGT
BRAF-3	TGSGTGTGATCTGACCTAGTAACCC	GTA AACGACGGCCAGTCCATATGGCCCTACAGTATTTCTTC	GTA AACGACGGCCAGT
BRAF-4	GTA AACGACGGCCAGTCCCTCCTCAGTCTACTAGCCC	TTACTTCCATATTTCAACATCCC	GTA AACGACGGCCAGT
BRAF-5	GTA AACGACGGCCAGTGTGATCCATCTATTATCTTGAACCC	GGGAGAAATACTGCTCCATCCC	GTA AACGACGGCCAGT
BRAF-6	GTGTTTCTGAGAATGAAATTTGA	GTA AACGACGGCCAGTCTGAGTGGTATGATAAGTTATTTGGG	GTA AACGACGGCCAGT
BRAF-7	GTA AACGACGGCCAGTGGCAGTTGGCAGTATTGGATT	TCATCAGAGAAACAGCAAGC	GTA AACGACGGCCAGT
BRAF-8	GTA AACGACGGCCAGTGGTTTACATTTGCAAGTGGCTC	GTACTTGAAGAGGCAAGTATAAAGG	GTA AACGACGGCCAGT
BRAF-9	GTA AACGACGGCCAGTGGCCCATCTCTTCCA	GCAGTGGCTAGAAATATGCTT	GTA AACGACGGCCAGT
BRAF-10	CTTCTGATCCCTCTCAGGC	GTA AACGACGGCCAGTGGCAAGTGAATATTTCTTGTGATG	GTA AACGACGGCCAGT
BRAF-11	GTA AACGACGGCCAGTCCATGGAAACAACAGGTTGG	AATAGTTGCTACCCTGGGAACC	GTA AACGACGGCCAGT
BRAF-12	CAATGGCAGTCTCTTAAATGATC	GTA AACGACGGCCAGTTTACATCCTTATGTTCTGGAC	GTA AACGACGGCCAGT
BRAF-13	GTA AACGACGGCCAGTGGATAAATAGGCTGACTGG	CTATACATGCATGCAATCCC	GTA AACGACGGCCAGT
BRAF-14	TCATCTACACATTTCAAGCC	GTA AACGACGGCCAGTGTGTAATCTGGGAATCTGAA	GTA AACGACGGCCAGT
BRAF-15	GAATTCATCTGGCAATGATGGT	GTA AACGACGGCCAGTTCACGCTTACCCAGGATTA	GTA AACGACGGCCAGT
BRAF-16	CCATCTATGATGGCATTGG	GTA AACGACGGCCAGTCTCAACCTCATGAAGCCATC	GTA AACGACGGCCAGT
BRAF-17	GCTTTCTTGAAGTGTGATGGG	GTA AACGACGGCCAGTCCACAGATGTTCTTGGTTC	GTA AACGACGGCCAGT
RAF-1	GTA AACGACGGCCAGTCTGGTCCATTTTCCATC	ATAGGGGGTGGGAAGAAC	GTA AACGACGGCCAGT
RAF-2	GTA AACGACGGCCAGTATTTCTGTGCCACCTTCC	AGGTATTGGTCTCAGGGCC	GTA AACGACGGCCAGT
RAF-3	GTA AACGACGGCCAGTGGCCTTGAGCAAAATACCTTC	TTGCCTTACTGTAACCAACAGCA	GTA AACGACGGCCAGT
RAF-4	GTA AACGACGGCCAGTGGAGGCCAAGTAAGTTG	ATGAAATGCCACAACCTAGC	GTA AACGACGGCCAGT
RAF-5	GTA AACGACGGCCAGTAAAGCAAGCATGATGG	CCAGAAAGCAGCAAGG	GTA AACGACGGCCAGT
RAF-6	GTA AACGACGGCCAGTGGTGTACAGTGAAGTTGGCC	TCCTTGATCAGATTTGAAACCC	GTA AACGACGGCCAGT
RAF-7	GTA AACGACGGCCAGTGAATAATCAGCCTTGAGA	TTGGCAGGAGTACTGTGTC	GTA AACGACGGCCAGT
RAF-8	GGATGCAATTCGAAGTCAAC	GTA AACGACGGCCAGTGTCTGATGCAAGTGGC	GTA AACGACGGCCAGT
RAF-9	AACAGATGACATGGGTTGATCC	GTA AACGACGGCCAGTCTCAGTCCCTCTCCCTG	GTA AACGACGGCCAGT
RAF-10	GTA AACGACGGCCAGTGAATAATGCCGATCTGTG	GGGCCACAGTCCACTAATC	GTA AACGACGGCCAGT
RAF-11	GTA AACGACGGCCAGTGACAGCAGAAACCACTGTC	GGCTTGTGCAAGATATCACAG	GTA AACGACGGCCAGT
RAF-12	GTA AACGACGGCCAGTCCCTGTGTGTAACACTCCTTGG	TTGCTGCTCTGCTCTTTTC	GTA AACGACGGCCAGT
RAF-13	GCTGTGACAGTGAAGTGG	GTA AACGACGGCCAGTATGCAATTCGCCCTGAGGC	GTA AACGACGGCCAGT
RAF-14	GTA AACGACGGCCAGTAAATGAAGGGACAGCCTGG	AGCCTTCTATTGCTTTGGG	GTA AACGACGGCCAGT
RAF-15	CAGGTAAGTGTGCTGGTGC	GTA AACGACGGCCAGTCCATCTTAGAGGACCTGGG	GTA AACGACGGCCAGT
RAF-16	CCAGCTCCTCTACAAGTGG	GTA AACGACGGCCAGTAAACATGTGTTGCTGCTGG	GTA AACGACGGCCAGT
HRAS-1	TGGGCTAATAGAGCAAGTGG	GTA AACGACGGCCAGTGAAGGAAGCAGGAGACAGG	GTA AACGACGGCCAGT
HRAS-2	GTA AACGACGGCCAGTGAAGGCTGGCTGTGAAC	GACATCGCCAGAGGAGACAG	GTA AACGACGGCCAGT
HRAS-3	TTCTGTGTGTTTGGCCATC	GTA AACGACGGCCAGTGTGAGTGTGCTCCCTGG	GTA AACGACGGCCAGT
HRAS-4	GCCTCTGTGCTCTCTGC	GTA AACGACGGCCAGTGTCTCCCAAGGACCTC	GTA AACGACGGCCAGT
KRAS-1	GTA AACGACGGCCAGTAAAGCCACTGTGAAGCTGGT	AGAGAAGCAGGCCATAGGTTG	GTA AACGACGGCCAGT
KRAS-2	GTA AACGACGGCCAGTGTCCGAGTGAAGATATGG	TTTCAATGCTCTCTCCCTC	GTA AACGACGGCCAGT
KRAS-3	GTA AACGACGGCCAGTAAAGCTTGGCATGCTCCTGAC	ACTCGATCAGACACAGGC	GTA AACGACGGCCAGT
KRAS-4	ATTTCCACATTCGAGGCTGAG	GTA AACGACGGCCAGTGCAATGCTAACATGGGAAGG	GTA AACGACGGCCAGT
NRAS-1	GTA AACGACGGCCAGTCCAAATGGAAGTCAACACTAGG	GAATCAACACTGAGTTTGAATG	GTA AACGACGGCCAGT
NRAS-2	GTA AACGACGGCCAGTAAAGCATGCAATCCCTGTG	CTGTGTTCCAGTCAATCCC	GTA AACGACGGCCAGT
NRAS-3	GTA AACGACGGCCAGTAAAGCATGCTGCCCTCCTCAG	CAAGACAGAGGCTGCAAGT	GTA AACGACGGCCAGT
NRAS-4	GCCTGTTCTGTGATCAATAGG	GTA AACGACGGCCAGTGTGCAGAGGATAGGCCAG	GTA AACGACGGCCAGT

^aThe primer pair did not meet our quality criteria that >90% of bases in the target region have a Phred quality score of at least 20 in three quarters of the tumor samples analyzed.

Table S7. Primers used for ERBB4 plasmid construction

Gene Name	Forward Primer	Reverse Primer
ERBB4 into pCDF-MCS2-EF1-Puro™	CGGCTCTAGAGCCACCATGAAAGCCGGCGAC	ATCGGGCGGCGCTTACACCACAGTATTCGG
Knockdown resistant ERBB4 primers into pCDF1-MCS2-EF1-puro	CACCAAAATCAAGGGGACTT	GGAGCCAGTACACGACATCA
Knockdown resistant ERBB4 primer set #1 into pcDNA3.1	GATTCCTGTGGCCATTAAGATTCT	AGAATCTTAATGGCCACAGGAATC
Knockdown resistant ERBB4 primer set #2 into pcDNA3.1	CCTGTGGCCATCAAGATTCT	AGAATCTTGTATGGCCACAGG
Knockdown resistant ERBB4 primer set #3 into pcDNA3.1	CCTGTGGCCATCAAAATCTTAATGAGAC	GTCTCATTAAAGAATTTGATGGCCACAGG

Supplementary Note
Tumor Tissue Collection

A panel of 79 pathology-confirmed metastatic melanoma tumor resections was assembled from patients referred to the Surgery Branch of the National Cancer Institute for enrollment in IRB-approved Surgery Branch clinical trials of immunotherapy. All of the patients had progressive metastatic melanoma that had failed available conventional treatments, were 16 years or older and passed eligibility testing for the relevant protocol. None had received therapy for 1 month prior to entering the protocol. Before tissue was acquired all patients signed written informed consents. The melanoma tissue panel was selected on the basis of an available pathology-confirmed, melanoma tissue culture line, paired with freshly frozen tissue from the resected melanoma metastasis and apheresis-collected, peripheral blood mononuclear cells.